Method for isolating neural cells with tenascin-R connections

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses a novel method for isolating and purifying neural cells, particularly oligodendrocytes, from vertebrate neural tissue. The method uses a tenascin-R probe (a specific fragment or fusion protein derived from the tenascin-R extracellular matrix protein) to specifically select and bind neural cells from a suspension. This process allows for efficient, single-step, and highly pure isolation of oligodendrocytes or other neural cells. Additionally, it covers the preparation of tenascin-R probes and related tools (vectors, antibodies, kits), as well as applications in cell culture, research, diagnostics, therapeutics, and regenerative medicine.

Use CasesContent extracted from patent full text and abstract with AI.

• Preparation of highly pure oligodendrocyte populations for neurobiological research.
• In vitro differentiation of neural or mesenchymal stem cells into neural or oligodendrocyte cells for basic research or therapeutic development.
• Development of cell-based assays for studying neurodegenerative diseases such as multiple sclerosis (MS) and periventricular leukomalacia (PVL).
• Manufacture of diagnostic kits or research reagents for isolating specific neural cell types.
• Screening of drug candidates for effects on neural cell survival, differentiation, or remyelination.
• Cell therapy or regenerative medicine protocols targeting demyelinating diseases and traumatic nerve injuries by producing neural cells for transplantation.
• Production of monoclonal antibodies specific for tenascin-R for analytical and therapeutic purposes.

BenefitsContent extracted from patent full text and abstract with AI.

• Allows for the rapid and highly efficient isolation of pure neural cell populations, especially oligodendrocytes, in a single step, saving time and increasing yield compared to traditional multi-step or antibody-based methods.
• Supports the differentiation and survival of neural or mesenchymal stem cells into desired cell types, enabling advanced in vitro models and cell supply for therapy.
• Reduces contamination with unwanted cell types, facilitating more reliable experiments and therapeutic cell preparation.
• Enables cross-species utility—tenascin-R probes from one species can isolate cells from another—providing flexibility for animal models and translational studies.
• Provides a platform for the development of diagnostic and therapeutic products related to neurodegenerative diseases and nerve injury.
• Facilitates new methods for studying the molecular mechanisms of neural differentiation and disease, as well as screening and development of regenerative drugs.
• The associated tools (e.g., recombinant proteins, antibodies, and kits) broaden the accessibility and versatility of the invention for research and clinical applications.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

Isolation and purification of neural cells from primary neural tissue of vertebrates, comprises selection of cells from a single cell suspension using a tenascin-R-containing probe (tenascin-R-probe), which is (a) N-terminal fragment of native tenascin-R, which corresponds to human tenascin-R fragment encoded by nucleotides 151-648 of SEQ ID NO: 1, (b) homologs and fragments of (a), and (c) fusion proteins comprising a domain with (a) or (b) (where the sequence not defined here may be found at ftp://ftp.wipo.int/pub/published pct sequences/publication). Independent claims are included for: (1) the tenascin-R-fragment or tenascin-R-fusion protein; (2) a DNA, which encodes the tenascin-R-fragment or tenascin-R-fusion protein; (3) a vector comprising the DNA; (4) a host organism is transformed or transfected with the vector and/or comprising the DNA; (5) preparing tenascin-R-fragment or tenascin-R-fusion protein, comprising culturing the host organism; (6) an antibody obtained by immunizing a suitable host organism with the tenascin-R-fragment; (7) a cell line or hybridoma cell line that produces a monoclonal antibody; (8) a kit comprising tenascin-R-probe and/or vector, which encodes for the tenascin-R probe and/or a test culture of a cell line that is suitable for expressing tenascin-R-probe; and (9) producing oligodendrocytes from isolated stem cells in vitro, comprising incubating the stem cells in the presence of tenascin-R-fragment or tenascin-R fusion protein. ACTIVITY : Neuroprotective; Cerebroprotective; Vasotropic; Vulnerary. MECHANISM OF ACTION : None given.